Rchr
J-GLOBAL ID：201801017391679558
Update date: Sep. 01, 2020
Ohba Motoi
Ohba Motoi
Contact this researcher
You can send email directly to the researcher.
Papers (60)：
Toshimitsu Yamaoka, Motoi Ohba, Tohru Ohmori. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2017. 18. 11
Toshimitsu Yamaoka, Motoi Ohba, Satoru Arata, Tohru Ohmori. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure. JOVE-JOURNAL OF VISUALIZED EXPERIMENTS. 2017. 126
Toshimitsu Yamaoka, Tohru Ohmori, Motoi Ohba, Satoru Arata, Yasunori Murata, Sojiro Kusumoto, Koichi Ando, Hiroo Ishida, Tsukasa Ohnishi, Yasutsuna Sasaki. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. MOLECULAR CANCER RESEARCH. 2017. 15. 7. 915-928
Toshimitsu Yamaoka, Tohru Ohmori, Motoi Ohba, Satoru Arata, Yasunari Kishino, Yasunori Murata, Sojiro Kusumoto, Hiroo Ishida, Takao Shirai, Takashi Hirose, et al. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. MOLECULAR CANCER THERAPEUTICS. 2016. 15. 12. 3040-3054
Yoko Toba Ichihashi, Toshimitsu Yamaoka, Tohru Ohmori, Motoi Ohba. Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells. Biochemistry and Biophysics Reports. 2016. 5. 1-7
ｍore...
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in
researchmap
.
For details, see here
.
Return to Previous Page
TOP
BOTTOM
